OMN 51
Alternative Names: OMN-51Latest Information Update: 23 Nov 2022
At a glance
- Originator Omnix Medical
- Class Antibacterials; Cyclic peptides
- Mechanism of Action Bacterial outer membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 03 Nov 2022 Omnix Medical intends file patent for OMN 51 (Omnix Medical pipeline, November 2022)
- 03 Nov 2022 Preclinical studies in Cystic fibrosis-associated respiratory tract infections in Israel (unspecified route) before November 2022 (Omnix Medical pipeline, November 2022)
- 03 Nov 2022 Omnix Medical plans to initiate clinical trials for OMN 51(Omnix Medical pipeline, November 2022)